CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Comparing Palliative Stereotactic Body Radiotherapy vs. Palliative Standard Radiotherapy in Patients with Advanced Head and Neck Cancer
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab or Botensilimab Alone vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy. Trials currently under CCTG's DSMC oversight include:
These CCTG trials have been formally permanently closed/terminated. No further ethics approvals or folow up data are required, more information can be found on the CCTG website under the "Toolbox".
CCTG trials BL13 and IND237 have been centrally activated with further information please visit the trial pages.
This is a reminder to obscure all personal identifiers of participants from reports and correspondence sent to CCTG and to provide an update on our privacy breach process. The Canadian Cancer Trials Group has recently sent an email to Centre Representatives and Contact Clinical Research Associates on December 21, 2018 outlining how to prevent a privacy breach and what to expect if one occurs.
The results of the Unicancer and the Canadian Cancer Trials Group (CCTG) PRODIGE 24 | CCTG PA.6 study have been published in the New England Journal of Medicine. The practice changing results indicate a significant improvement in the survival of pancreatic cancer patients treated with the mFOLFIRINOX chemotherapy compared to the current standard treatment with gemcitabine
Congratulations to Professor Janette Vardy (University of Sydney) and Doctor Haryana Dhillon (University of Sydney) who were successful in their funding application to the National Health and Medical Research Council (NHMRC) to continue the CCTG led CHALLENGE (CO.21) trial in Australia
As we embark on a new year, it is time to reflect on what we have accomplished together this year and what 2019 will bring. It has been a busy year with continued growth and expansion across our national and international networks.
Congratulations to the researchers who presented abstracts at the American Society of Hematology Annual Meeting (ASH) and San Antonio Breast Cancer Symposium.
